Phase I Study of T-Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this phase I trial is to evaluate the safety and feasibility of mesothelin-specific T-cells (FH-TCR-TMSLN) in patients with metastatic pancreatic cancer.
Study ID: RG1007292
Trial Phase: Phase I
Trial Sponsor: Fred Hutchinson Cancer Research Center
Therapies Used in This Trial: FH-TCR-TMSLN